Citations

Showing 10 of 108152 citations.

Hemoglobinuria in the Early Poststem-Cell–Transplant Period: Risk Factors and Association with Outcomes
Kompotiatis, Panagiotis , Manohar, Sandhya , Hogan, William J. , Nath, Karl A. , Leung, Nelson , Alkhateeb, Hassan B , Hogan, William J , Nath, Karl A , Leung, Nelson , Alkhateeb, Hassan B.

Mayo Clinic

Kidney360 | August 25, 2021 | Volume: 2 | Issue: 10 | Pages: 1569-1575

10.34067/kid.0002262021 | PMID 35372983 Get It

Key Points Post-HSCT hemoglobinuria was associated with graft type (BMT+Cord). Post-HSCT hemoglobinuria was associated with early (48–72 hours) post-HSCT AKI. Graft type (BMT+Cord) was associated with AKI among patients with hemoglobinuria. Background Information on risk factors of hemoglobinuria after hematopoietic stem-cell transplant (HSCT) and its association with AKI, mortality, and engraftment is limited. Methods We conducted a retrospective cohort study on all consecutive adults that underwent HSCT from January 6, 1999, to November 6, 2017. The study included 6039 patients that underwent bone marrow transplantation (BMT), umbilical cord blood, and peripheral blood stem-cell transplantation (PBSCT). Results Early post-HSCT, AKI occurred in 393 (7%) patients, and 52 (0.9%) patients had post-HSCT hemoglobinuria. Post-HSCT hemoglobinuria was associated with graft type (BMT+Cord), underlying disease (lymphoma, acute leukemia), and fludarabine-based conditioning regimen. Post-HSCT hemoglobinuria was associated with early (48–72 hours) post-HSCT AKI. Graft type (BMT+Cord) was associated with AKI among patients with hemoglobinuria. AKI in patients with hemoglobinuria was associated with delayed platelet engraftment and delayed WBC engraftment but not 100-day mortality. Conclusion Close monitoring is recommended in this patient group to facilitate a good engraftment outcome.
Outcomes of Lymphovenous Anastomosis for Upper Extremity Lymphedema: A Systematic Review
Verhey, Erik M., Torres‐Guzman, Ricardo A. , Forte, Antonio J. , Rebecca, Alanna M. , Teven, Chad M. , Torres-Guzman, Ricardo A, Ávila, Francisco R. , Jorge Forte, Antonio, Forte, Antonio Jorge , Torres, Ricardo A , Gupta, Nikita

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | August 25, 2021 | Volume: 9 | Issue: 8 | Pages: e3770

10.1097/gox.0000000000003770 | PMID 34476159 Get It

Background: Lymphovenous anastomosis (LVA) is an accepted microsurgical treatment for lymphedema of the upper extremity (UE). This study summarizes and analyzes recent data on the outcomes associated with LVA for UE lymphedema at varying degrees of severity. Methods: A literature search was conducted in the PubMed database to extract articles published through June 19, 2020. Studies reporting data on postoperative improvement in limb circumference/volume or subjective improvement in quality of life for patients with primary or secondary lymphedema of the UE were included. Extracted data consisted of demographic data, number of patients and upper limbs, duration of symptoms before LVA, surgical technique, follow-up, and objective and subjective outcomes. Results: A total of 92 articles were identified, of which 16 studies were eligible for final inclusion comprising a total of 349 patients and 244 upper limbs. The average age of patients ranged from 38.4 to 64 years. The duration of lymphedema before LVA ranged from 9 months to 7 years. The mean length of follow-up ranged from 6 months to 8 years. Fourteen studies reported an objective improvement in limb circumference or volume measurements following LVA, ranging from 0% to 100%. Patients included had varying severity of lymphedema, ranging from Campisi stage I to IV. The maximal improvement in objective measurements was found in patients with lower stage lymphedema. Conclusion: LVA is a safe, effective technique for the treatment of UE lymphedema refractory to decompressive treatment. Results of LVA indicate greater efficacy in earlier stages of lymphedema before advanced lymphatic sclerosis.
Incidence, prevalence, and predictors of inflammatory arthritis in patients with hidradenitis suppurativa: a systematic review and meta‐analysis
Hanna, Nardin , Silverberg, Orli M. , Reaume, Michael , Davis, Mark D.P. , Piguet, Vincent , Piguet, V , Gladman, Dafna D. , Alavi, Afsáneh

Mayo Clinic

International Journal of Dermatology | August 25, 2021 | Volume: 61 | Issue: 9 | Pages: 1069-1079

10.1111/ijd.15860 | PMID 34432308 Get It

AbstractAn increasing amount of evidence has emerged suggesting that hidradenitis suppurativa (HS) is associated with inflammatory arthritis. This study reviewed the incidence, prevalence, and predictors of inflammatory arthritis in patients with HS. A comprehensive literature search was conducted in CINAHL, Embase, and Medline from inception to February 14, 2020. Articles were included in the review if they provided data on disease epidemiology or predictors of adult or pediatric HS patients with comorbid inflammatory arthritis. There are no validated diagnostic criteria for HS, thus we considered patients as having HS if they had at least one diagnostic code in a hospital or claims database or a diagnosis of HS/inflammatory arthritis in a medical record. The same criteria were used to confirm presence of inflammatory arthritis. We identified an increased incidence of rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriatic arthritis (PsA) in HS patients when compared with estimates in the general population. We identified a relatively high prevalence of RA, spondyloarthritis (SpA), and PsA in HS patients when compared with estimates in the general population. There was evidence to suggest that patients who are younger than 30, male, have severe HS, or are taking infliximab or adalimumab (which may also be confounded by HS disease severity) may be at greater risk for specific subtypes of inflammatory arthritis. However, further data are needed to confirm these associations. The increased incidence and prevalence of inflammatory arthritis within HS patients underscore the need for increased awareness and interdisciplinary partnership within rheumatology and dermatology.
Controversy on the Association of the Critical Shoulder Angle and the Development of Degenerative Rotator Cuff Tears: Is There a True Association? A Meta-analytical Approach
Liévano, Jorge Rojas , Bautista, María , Woodcock, Santiago, Fierro, Guido , González, Juan Carlos , Rojas Lievano, Jorge, Lievano, Jorge Rojas

Mayo Clinic

The American Journal of Sports Medicine | August 25, 2021 | Volume: 50 | Issue: 9 | Pages: 2552-2560

10.1177/03635465211027305 | PMID 34432551 Get It

Background: The role of the critical shoulder angle (CSA) as a risk factor for rotator cuff tear (RCT) remains controversial. Studies on the association between the CSA and RCT show considerable differences in design, and this could be responsible for the variation in study results. Purpose: To (1) describe the reliability of CSA measurement and (2) evaluate the results of the studies reporting the association between the CSA and RCT using meta-analytical techniques to explore potential sources of variation of study results. Study Design: Systematic review and meta-analysis; Level of evidence, 4. Methods: MEDLINE, EMBASE, and CINAHL electronic databases were searched through June 30, 2019. Case-control and cross-sectional studies reporting the association of the CSA and RCT were selected. The weighted mean difference in the CSA was estimated using a random-effects model. Prediction interval was computed to better express uncertainties in the effect estimate. Metaregression and subgroup analyses were performed to explore potential sources of heterogeneity. Results: A total of 14 studies, including 1154 cases and 1271 controls, were identified. Of these studies, 79% (11/14) assessed the reliability of the CSA measurement, demonstrating an excellent intraobserver (range, 0.91-0.99) and interobserver (range, 0.87-0.99) reliability. Compared with controls, cases with RCT showed larger measurements of the CSA (3.3° [95% CI, 2.3°- 4.4°]). However, there was a high heterogeneity ( I 2 = 93%), and the 95% prediction interval (-0.4° to 7.1°) included no difference in the CSA. Results of the metaregression analysis showed a significant association of several methodological aspects with the heterogeneity. The difference in the CSA tended to be larger when only full-thickness tears were included, when no specific defined criterion for assessing radiographic viewing perspective was used, in studies with smaller sample sizes, and in studies at higher risk of bias. Conclusion: While the CSA can be reliably measured, the difference in the CSA between cases and controls varied from very large to modest or almost no difference. Several determinants of heterogeneity were determined. Owing to this heterogeneity, it is difficult to gain an insight into the strength and exact nature of the association between the CSA and RCT with the current evidence.
Peripheral nerve block anesthesia/analgesia for patients undergoing primary hip and knee arthroplasty: recommendations from the International Consensus on Anesthesia-Related Outcomes after Surgery (ICAROS) group based on a systematic review and meta-analys
Memtsoudis, Stavros G. , Cozowicz, Crispiana , Bekeris, Janis, Bekere, Dace, Liu, Jiabin , Soffin, Ellen M. , Mariano, Edward R. , Johnson, Rebecca L. , Go, George , Hargett, Mary J. , Lee, Bradley H. , Wendel, Pamela , Brouillette, Mark , Kim, Sang Jo, Baaklini, Lila , Wetmore, Douglas S., Hong, Genewoo , Goto, Rie , Jivanelli, Bridget , Athanassoglou, Vassilis , Αrgyra, Eriphili, Barrington, Michael J. , Borgeat, Alain , El‐Boghdadly, Kariem , Elkassabany, Nabil , Gautier, Philippe , Gerner, Peter, Valle, Alejandro González Della , Goytizolo, Enrique A. , Guo, Zhenggang , Hogg, Rosemary , Kehlet, Henrik , Kessler, Paul, Lavand"homme, Patricia, Macfarlane, Alan , McIsaac, Dan , Neal, Joseph M. , Peng, Philip , Pichler, Lukas, Poultsides, Lazaros, Sites, Brian D. , Stundner, Ottokar , Sun, Eric, Viscusi, Eugene R. , Votta‐Velis, E. Gina, YaDeau, Jacques T. , Sharrock, Nigel E. , Barrington, Michael John , El-Boghdadly, K , Elkassabany, Nabil M , Kopp, Sandra , Mantilla, Carlos, Neal, Joseph M , Poeran, Jashvant , Schwenk, Eric S , Stundner, Ottokar , Viscusi, Eugene , Wu, Christopher L , Mariano, Edward R , Johnson, Rebecca L , Soffin, Ellen M , Macfarlane, Alan James Robert , Andrés, José De , Kessler, Paul, Kopp, Sandra L. , Lavand"homme, Patricia, MacLean, Catherine H. , Mantilla, Carlos B. , McLawhorn, Alexander S. , Parks, Michael L. , Parvizi, Javad , Schwenk, Eric S.

Mayo Clinic

Regional Anesthesia & Pain Medicine | August 25, 2021 | Volume: 46 | Issue: 11 | Pages: 971-985

10.1136/rapm-2021-102750 | PMID 34433647 Get It

Background Evidence-based international expert consensus regarding the impact of peripheral nerve block (PNB) use in total hip/knee arthroplasty surgery. Methods A systematic review and meta-analysis: randomized controlled and observational studies investigating the impact of PNB utilization on major complications, including mortality, cardiac, pulmonary, gastrointestinal, renal, thromboembolic, neurologic, infectious, and bleeding complications. Medline, PubMed, Embase, and Cochrane Library including Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, NHS Economic Evaluation Database, were queried from 1946 to August 4, 2020. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to assess evidence quality and for the development of recommendations. Results Analysis of 122 studies revealed that PNB use (compared with no use) was associated with lower ORs for (OR with 95% CIs) for numerous complications (total hip and knee arthroplasties (THA/TKA), respectively): cognitive dysfunction (OR 0.30, 95% CI 0.17 to 0.53/OR 0.52, 95% CI 0.34 to 0.80), respiratory failure (OR 0.36, 95% CI 0.17 to 0.74/OR 0.37, 95% CI 0.18 to 0.75), cardiac complications (OR 0.84, 95% CI 0.76 to 0.93/OR 0.83, 95% CI 0.79 to 0.86), surgical site infections (OR 0.55 95% CI 0.47 to 0.64/OR 0.86 95% CI 0.80 to 0.91), thromboembolism (OR 0.74, 95% CI 0.58 to 0.96/OR 0.90, 95% CI 0.84 to 0.96) and blood transfusion (OR 0.84, 95% CI 0.83 to 0.86/OR 0.91, 95% CI 0.90 to 0.92). Conclusions Based on the current body of evidence, the consensus group recommends PNB use in THA/TKA for improved outcomes. Recommendation: PNB use is recommended for patients undergoing THA and TKA except when contraindications preclude their use. Furthermore, the alignment of provider skills and practice location resources needs to be ensured. Evidence level: moderate; recommendation: strong.
Natural History and Progression of Transthyretin Amyloid Cardiomyopathy: Insights from ATTR-ACT
Nativi-Nicolau, José , Gundapaneni, Balarama, Keohane, Denis, Sultan, Marla B. , Grogan, Martha , Judge, Daniel P. , Hoffman, James E.

Mayo Clinic

ESC Heart Failure | August 25, 2021 | Volume: 8 | Issue: 5 | Pages: 3875-3884

10.1002/ehf2.13541 | PMID 34432383 Get It

Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, fatal disorder that remains underdiagnosed. The Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) was the first large clinical trial to include both wild-type (ATTRwt) and hereditary (ATTRv) patients. A description of the natural history of ATTR-CM, utilizing data from placebo-treated patients in ATTR-ACT, will provide a greater understanding of presentation and progression of ATTR-CM and may aid in disease awareness, earlier diagnosis and treatment monitoring. Methods and results Changes in clinical endpoints (mortality, cardiovascular [CV]-related hospitalizations, 6-min walk test [6MWT] distance and Kansas City Cardiomyopathy Questionnaire Overall Summary [KCCQ-OS] score) from baseline to Month 30 in the 177 patients (134 ATTRwt, 43 ATTRv) who received placebo in ATTR-ACT were assessed. ATTRwt patients tended to have less severe disease at baseline. Over the duration of ATTR-ACT, there were 76 (42.9%) all-cause deaths, and 107 (60.5%) patients had a CV-related hospitalization. There was a lower proportion of all-cause deaths in ATTRwt (49, 36.6%) than ATTRv (27, 62.8%). There was a similar, steady decline in mean (SD) 6MWT distance from baseline to Month 30 in ATTRwt (93.9 [93.7] m) and ATTRv (89.1 [107.2] m) patients. The decline in mean (SD) KCCQ-OS score was less severe in ATTRwt (13.8 [20.7]) than ATTRv (21.0 [26.4]) patients. Conclusions Patients with ATTR-CM experience a severe, progressive disease. In ATTR-ACT, placebo-treated patients with ATTRv, compared with ATTRwt, had more severe disease at baseline, and their disease progressed more rapidly as shown by mortality, hospitalizations and quality of life over time.
TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas
González-Buendía, Edgar , Zhao, Junfei , Mukherjee, Subhas, Zhang, Daniel Y. , Feldstein, Eric , Kang, Seong Jae , Lee-Chang, Catalina , Mahajan, Aayushi , Chen, Li , Karan, Charles , Magnuson, Lisa, Marshall, Stacy A. , Mohyeldin, Ahmed, Nakano, Ichiro , Bansal, Mukesh , James, C. David , Ahmed, Atique U. , Canoll, Peter , Shilatifard, Ali , Zhang, Daniel , Realubit, Ronald , Karan, Charles , Ahmed, Atique , Sonabend, Adam M , Wang, Lu , Mukherjee, Subhas, Arrieta, Victor Andrés , KANE, JOSHUA ROBERT , Horbinski, Craig , Sarkaria, Jann N. , Brat, Daniel J. , Rabadán, Raúl

Mayo Clinic

Clinical Cancer Research | August 25, 2021 | Volume: 27 | Issue: 20 | Pages: 5669-5680

10.1158/1078-0432.ccr-21-0312 | PMID 34433651 Get It

Abstract Purpose: The epigenetic mechanisms involved in transcriptional regulation leading to malignant phenotype in gliomas remains poorly understood. Topoisomerase IIB (TOP2B), an enzyme that decoils and releases torsional forces in DNA, is overexpressed in a subset of gliomas. Therefore, we investigated its role in epigenetic regulation in these tumors. Experimental Design: To investigate the role of TOP2B in epigenetic regulation in gliomas, we performed paired chromatin immunoprecipitation sequencing for TOP2B and RNA-sequencing analysis of glioma cell lines with and without TOP2B inhibition and in human glioma specimens. These experiments were complemented with assay for transposase-accessible chromatin using sequencing, gene silencing, and mouse xenograft experiments to investigate the function of TOP2B and its role in glioma phenotypes. Results: We discovered that TOP2B modulates transcription of multiple oncogenes in human gliomas. TOP2B regulated transcription only at sites where it was enzymatically active, but not at all native binding sites. In particular, TOP2B activity localized in enhancers, promoters, and introns of PDGFRA and MYC, facilitating their expression. TOP2B levels and genomic localization was associated with PDGFRA and MYC expression across glioma specimens, which was not seen in nontumoral human brain tissue. In vivo, TOP2B knockdown of human glioma intracranial implants prolonged survival and downregulated PDGFRA. Conclusions: Our results indicate that TOP2B activity exerts a pleiotropic role in transcriptional regulation of oncogenes in a subset of gliomas promoting a proliferative phenotype.
RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Zinzani, Pier Luigi , Rodgers, Thomas, Marino, Dario , Frezzato, Maurizio, Barbui, Anna Maria, Castellino, Claudia, Meli, Erika, Fowler, Nathan H., Salles, Gilles , Feinberg, Bruce A. , Kurukulasuriya, Nuwan C., Tillmanns, Sascha, Parche, Stephan, Dey, Debarshi, Fingerle-Rowson, Günter, Ambarkhane, Sumeet, Winderlich, Mark, Nowakowski, Grzegorz S., Rodgers, Thomas D. , Feinberg, Bruce , Zinzani, Pier Luigi , Salles, Gilles A , Marino, Dario , Frezzato, Maurizio, Barbui, Anna Maria, Castellino, Claudia, Meli, Erika, Fowler, Nathan H., Kurukulasuriya, Nuwan C., Tillmanns, Sascha, Parche, Stephan, Dey, Debarshi, Fingerle-Rowson, Günter, Ambarkhane, Sumeet, Winderlich, Mark, Nowakowski, Grzegorz S.

Mayo Clinic

Clinical Cancer Research | August 25, 2021 | Volume: 27 | Issue: 22 | Pages: 6124-6134

10.1158/1078-0432.ccr-21-1471 | PMID 34433649 Get It

Abstract Purpose: Tafasitamab, an Fc-modified, humanized, anti-CD19 monoclonal antibody, in combination with lenalidomide, demonstrated efficacy in transplant-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), in the single-arm, phase II L-MIND study (NCT02399085). RE-MIND, a retrospective observational study, generated a historic control for L-MIND to delineate the contribution of tafasitamab to the efficacy of the combination. Patients and Methods: Data were retrospectively collected from patients with R/R DLBCL treated with lenalidomide monotherapy for comparison with tafasitamab + lenalidomide–treated patients (L-MIND). Key eligibility criteria were aligned with L-MIND. Estimated propensity score–based Nearest Neighbor 1:1 Matching methodology balanced the cohorts for nine prespecified prognostic baseline covariates. The primary endpoint was investigator-assessed best overall response rate (ORR). Secondary endpoints included complete response (CR) rate, progression-free survival (PFS), and overall survival (OS). Results: Data from 490 patients going through lenalidomide monotherapy were collected; 140 qualified for matching with the L-MIND cohort. The primary analysis included 76 patients from each cohort who received a lenalidomide starting dose of 25 mg/day. Cohort baseline covariates were comparable. A significantly better ORR of 67.1% (95% confidence interval, 55.4–77.5) was observed for the combination therapy versus 34.2% (23.7–46.0) for lenalidomide monotherapy [odds ratio, 3.89 (1.90–8.14); P < 0.0001]. Higher CR rates were achieved with combination therapy compared with lenalidomide monotherapy [39.5% (28.4–51.4) vs. 13.2% (6.5–22.9)]. Survival endpoints favored combination therapy. Lenalidomide monotherapy outcomes were similar to previously published data. Conclusions: RE-MIND enabled the estimation of the additional treatment effect achieved by combining tafasitamab with lenalidomide in patients with R/R DLBCL.
Brain White Matter Structure and Amyloid Deposition in Black and White Older Adults: The ARIC‐PET Study
Walker, Keenan A. , Hughes, Timothy M. , Jack, Clifford R. , Knopman, David S. , Sharrett, A. Richey , Wong, Dean F. , Mosley, Thomas H. , Mosley, Thomas H. , Knopman, David S. , Hughes, Timothy M , Jack, Clifford R , Gottesman, Rebecca F , Walker, Keenan A , Silverstein, Noah J. , Zhou, Yun , Gottesman, Rebecca F.

Mayo Clinic

Journal of the American Heart Association | August 25, 2021 | Volume: 10 | Issue: 17 | Pages: No page available

10.1161/jaha.121.022087 | PMID 34431373 Get It

Background White matter abnormalities are a common feature of aging and Alzheimer disease, and tend to be more severe among Black individuals. However, the extent to which white matter abnormalities relate to amyloid deposition, a marker of Alzheimer pathology, remains unclear. This cross‐sectional study examined the association of white matter abnormalities with cortical amyloid in a community sample of older adults without dementia and examined the moderating effect of race. Methods and Results Participants from the ARIC‐PET (Atherosclerosis Risk in Communities‐Positron Emission Tomography) study underwent brain magnetic resonance imaging, which quantified white matter hyperintensity volume and microstructural integrity using diffusion tensor imaging. Participants received florbetapir positron emission tomography imaging to measure brain amyloid. Associations between measures of white matter structure and elevated amyloid status were examined using multivariable logistic regression. Among 322 participants (43% Black), each SD increase in white matter hyperintensity volume was associated with a greater odds of elevated amyloid (odds ratio [OR], 1.37; 95% CI, 1.03–1.83) after adjusting for demographic and cardiovascular risk factors. In race‐stratified analyses, a greater white matter hyperintensity volume was more strongly associated with elevated amyloid among Black participants (OR, 2.00; 95% CI, 1.15–3.50), compared with White participants (OR, 1.29; 95% CI, 0.89–1.89). However, the race interaction was not statistically significant ( P interaction=0.09). We found no association between white matter microstructure and elevated amyloid. Conclusions The results suggest a modest positive relationship between white matter hyperintensity and elevated amyloid in older adults without dementia. Although the results indicate that this association is nonsignificantly stronger among Black participants, these findings will need to be confirmed or refuted using larger multiracial cohorts.